Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $10.26 (market cap $4.08B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 31.4× Direxion Daily TSLA Bull 2X Shares's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily TSLA Bull 2X Shares for 15 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TSLL | VRTX | |
|---|---|---|
Market Cap | $4.08B | $128.16B |
Volume | 46,206,477 | 806,603 |
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $557.96 |
52-Week Low | $6.74 | $407.37 |
Typical Hold Time | 15 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.15, down 1.55% on the day. The overall technical signal is bullish, supported by moving averages, while oscillators are neutral. Recent news highlights its sensitivity to Tesla's stock movements, with a notable rally tied to Cybercab hype. As a leveraged ETF, it aims to deliver twice Tesla's daily returns, amplifying both gains and losses.
The outlook for TSLL is directly tied to Tesla's performance, offering high-risk, high-reward exposure. Key risks include volatility decay from daily rebalancing and dependence on Tesla-specific events. Investors seeking amplified Tesla returns may find opportunity, but must be wary of the inherent leverage risks in a volatile stock.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
